Google
AllShoppingImagesNews Maps Videos Books
Search tools
Archives
  • Recent
  • Past hour
  • Past 24 hours
  • Past week
  • Past month
  • Past year
  • Archives
Sorted by relevance
Clear

How A Drugmaker Gamed The System To Keep Generic Competition Away

NPR
Celgene Corp. has thwarted rival drugmakers eager to make cheaper versions of medicines for a form of blood cancer.
80 months ago

Celgene repeatedly raised Revlimid's price to hit aggressive sales targets, congressional probe finds

FiercePharma
A congressional probe outlines aggressive pricing strategies at Celgene just as executives head to the US Capitol to testify.
51 months ago

Sales targets and bonuses drove Celgene, Teva drug price hikes, lawmakers charge

BioPharma Dive
Years of relentless price increases taken by drugmakers Celgene and Teva on two widely used brand-name drugs were driven by company...
51 months ago

New prescription drug price hikes hit Black patients hard

NBC News
Black and Latino people use 10% to 40% fewer prescription drugs because of high costs, according to a report by Patients for Affordable Drugs.
3 months ago

Rep. Katie Porter ripped into pharma executive Mark Alles for repeated price hikes on the cancer drug Revlimid

Business Insider
Rep. Katie Porter of California grilled Celgene CEO Mark Alles on Wednesday over price hikes on a cancer drug that she said resulted in a bonus of half a...
51 months ago

A G.O.P. Senate Candidate Highlights His Drug Industry Career. Should He? (Published 2018)

The New York Times
The race for Senator Robert Menendez's seat has proved competitive in deeply blue New Jersey. His Republican opponent, Bob Hugin, built his...
75 months ago

Mayo Clinic, LifePoint Health sue pharmas over 'pay for delay' deals keeping blood cancer drug prices high

FierceHealthcare
Health systems say deals between Revlimid's owners, Celgene and Bristol-Myers Squibb, and other pharmas are anticompetitive and drive higher...
14 months ago

These Are the Loopholes Drug Companies Use to Keep Prices High

Bloomberg.com
Drugmakers are using a variety of strategies to extend the exclusivity period of their wares, keeping less expensive alternatives away from patients.
84 months ago

After discount row, NICE finally says yes to first line Revlimid

PMLiVE
NICE has recommended Celgene's Revlimid as a first line treatment in transplant ineligible multiple myeloma patients – a full four years after its European...
68 months ago

Cancer Medication Price-Fixing Class Action Settlement

Top Class Actions
A group of cancer patients have secured a $55M class action settlement ending allegations that the maker of Thalomid and Revlimid conspired to keep cheaper,...
37 months ago